UNIVERSITY HOSPITAL BIRMINGHAM NHS FOUNDATION TRUST

Their core work

University Hospital Birmingham is one of the UK's largest NHS teaching hospital trusts, providing acute and specialist clinical care while conducting translational medical research. In H2020, they contributed clinical trial infrastructure and patient cohort access for projects spanning kidney disease therapeutics, brain injury diagnostics, and HIV research. Their role centers on bridging laboratory science with real-world clinical application — offering the patient populations, clinical protocols, and regulatory experience needed to move therapies from bench to bedside.

What they specialise in

How they've shifted over time

UHB's early H2020 work (2015–2016) centered on advanced cell therapies for kidney disease and biomedical optics for brain trauma — both requiring direct clinical trial participation in a hospital setting. Their most recent project (REACH, 2019) shifted toward HIV and global health, suggesting a broadening from organ-specific clinical trials toward population-level health challenges with an international dimension. With no projects after 2019, their H2020 trajectory shows a modest but notable pivot from specialist therapeutics toward wider public health research.

UHB appears to be broadening from single-disease clinical trials toward international public health collaborations, though their H2020 activity ended in 2021 and future direction under Horizon Europe is unclear.

How they like to work

UHB has never coordinated an H2020 project, consistently serving as a clinical partner or third party within larger consortia. Despite only 4 projects, they have worked with 48 unique partners across 14 countries, indicating they join large, multi-site consortia rather than leading small teams. This profile is typical of a major hospital trust that provides clinical infrastructure and patient access while leaving scientific leadership to academic or research institute partners.

UHB has built a broad European network of 48 partners across 14 countries through just 4 projects, reflecting their participation in large multi-national consortia typical of clinical trial and MSCA training networks.

What sets them apart

UHB's distinctive value lies in being a major NHS hospital trust that can offer real clinical trial sites, diverse patient populations, and UK regulatory pathway experience within EU-funded consortia. Unlike university labs or research institutes, they bring the operational reality of a large acute care hospital — meaning therapies and diagnostics tested through UHB face genuine clinical conditions. For consortium builders, this means access to one of the UK's largest hospital systems with established infrastructure for multi-site international trials.

Highlights from their portfolio

• NEPHSTROM
  Largest project by funding (EUR 502,576), involving a Phase 1b/2a clinical trial of mesenchymal stromal cell therapy for diabetic kidney disease — a concrete translational medicine effort.
• REACH
  Most recent project (2019), focused on HIV among vulnerable populations across a Russian-European alliance, signaling a shift toward global health and international partnerships.